Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

52
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
52
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

193
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
193
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

336
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
336
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

723
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
723

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel dynamic risk score to predict clinically significant bleeding after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancer.

Journal of thrombosis and haemostasis : JTH·2026
Same author

A novel dynamic risk score to predict venous thromboembolism recurrences after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancer.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Pre-Implementation Assessment of a Sexual Health eClinic in Canadian Oncology Care.

Current oncology (Toronto, Ont.)·2025
Same author

Clinical profile of patients with comorbid IBD and MS, and associated service impact in England's secondary care setting: a retrospective cohort study.

BMJ open·2025
Same author

Supporting older adults with cancer and their support person through geriatric assessment and remote exercise and education: The SOAR study protocol.

Journal of geriatric oncology·2025
Same author

Reply by Authors.

The Journal of urology·2025

Related Experiment Video

Updated: Oct 8, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.9K

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation.

Mamas A Mamas1, Sarah Batson2, Kevin G Pollock3

  • 1Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, United Kingdom; Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom.

The American Journal of Cardiology
|December 24, 2021
PubMed
Summary

Apixaban shows lower stroke risk and bleeding events than rivaroxaban in nonvalvular atrial fibrillation (NVAF) patients. Real-world evidence suggests apixaban offers better safety without compromising efficacy.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.6K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.1K

Related Experiment Videos

Last Updated: Oct 8, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.9K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.6K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.1K

Area of Science:

  • Cardiology
  • Pharmacology
  • Real-World Evidence Studies

Background:

  • Nonvalvular atrial fibrillation (NVAF) increases stroke risk.
  • Direct oral anticoagulants (DOACs) like apixaban and rivaroxaban are used for stroke prevention.
  • Real-world data is crucial for comparing DOACs in diverse patient populations.

Purpose of the Study:

  • To compare the efficacy and safety of apixaban versus rivaroxaban for stroke prevention in NVAF patients.
  • To synthesize real-world evidence through a systematic review and meta-analysis.
  • To explore the influence of clinical risk scores on treatment outcomes.

Main Methods:

  • Systematic review and meta-analysis of 10 observational real-world evidence studies.
  • Inclusion of NVAF patients treated with apixaban or rivaroxaban.
  • Pooled analysis of hazard ratios (HRs) for stroke/systemic embolism and major bleeding events.

Main Results:

  • Apixaban was associated with a significantly lower hazard of stroke/systemic embolism (HR 0.88; 95% CI 0.81-0.95).
  • Major bleeding episodes were significantly lower with apixaban compared to rivaroxaban (HR 0.62; 95% CI 0.56-0.69).
  • Apixaban also showed a lower risk of gastrointestinal bleeding (HR 0.57; 95% CI 0.50-0.64).

Conclusions:

  • Apixaban demonstrates comparable efficacy to rivaroxaban for stroke prevention in NVAF.
  • Apixaban is associated with significantly lower rates of major and gastrointestinal bleeding.
  • Patient risk scores (CHA 2DS2-VASc, HAS-BLED) may guide DOAC selection for optimal outcomes.